Abstract：
This editorial prefaces the annual themed issue on safety pharmacology (SP) methods which has been published since 2004 in the Journal of Pharmacological and Toxicological Methods (JPTM). Here we highlight content derived from the 2023 Safety Pharmacology Society (SPS) meeting held in Brussels, Belgium. The meeting generated 138 abstracts, reproduced in the current volume of JPTM. As in prior years, the manuscripts reflect various areas of innovation in SP including in silico modeling of stroke volume, cardiac output and systemic vascular resistance, computational approaches that compare drug-induced proarrhythmic sensitivity of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), an evaluation of the utility of the corrected J-Tpeak and Tpeak-to-Tend parameters from the ECG as potential proarrhythmia biomarkers, and the applicability of nonclinical concentration-QTc (C-QTc) modeling of data derived from the conduct of the in vivo QTc study as a component of the core battery of safety pharmacology studies.
摘要：
这篇社论介绍了安全药理学（SP）方法的年度主题，该主题自2004年以来已在《药理学和毒理学方法杂志》（JPTM）上发表。在这里，我们重点介绍了在布鲁塞尔举行的2023年安全药理学会（SPS）会议的内容，比利时。会议产生了138份摘要，在JPTM的当前卷中复制。和往年一样,这些手稿反映了SP的各个领域的创新，包括每搏输出量的计算机建模，心输出量和全身血管阻力，比较人诱导多能干细胞衍生心肌细胞（hiPSC-CM）的药物诱导的致心律失常敏感性的计算方法，对来自ECG的校正后的J-Tpeak和Tpeak-to-Tend参数作为潜在的致心律失常生物标志物的效用进行评估,以及非临床浓度-QTc（C-QTc）建模数据的适用性，这些数据来自体内QTc研究，作为安全药理学研究核心组成部分。
